Haemonetics Corporation (NYSE: HAE) announced the publication of a retrospective cohort study evaluating outcomes of its VASCADE MVP XL venous vascular closure system in large-bore sheath electrophysiology procedures, according to a company press release dated Aug. 3, 2026.

The study, conducted at Emory University and funded by a grant from Haemonetics, included 1,623 patients who underwent procedures using sheaths up to 17F outer diameter, including pulsed field ablation for atrial fibrillation, left atrial appendage closure, and concomitant procedures. The company described it as the largest reported cohort using the VASCADE MVP XL system to date.

Results showed a median hemostasis time of 2 minutes, a 92.5% same-day discharge rate, a median time to discharge of 3.5 hours, and an overall vascular complication rate of 1.2%, with no surgical interventions required.

David B. De Lurgio, M.D., Medical Director of Electrophysiology at Emory Saint Joseph's Hospital and the study's corresponding author, noted that same-day discharge was consistently achieved even with sheaths larger than those historically used in device-based closure.

In March 2026, the U.S. Food and Drug Administration approved expanded labeling for the VASCADE MVP XL system to include procedures using 10-14F inner diameter and up to 17F outer diameter procedural sheaths. The device is approved for use alongside several PFA systems, including Abbott's Volt PFA System, Boston Scientific's FARAPULSE, and Medtronic's Sphere-9 catheter, as well as Boston Scientific's WATCHMAN TruSteer left atrial appendage closure solution.